Vistagen Therapeutics Profit Margin

The latest profit margin for VTGN is -2703.72% as of June 2026. That compares with -8634.67% in the prior-year period — up 68.7% year over year. That is below the Healthcare sector average of 9.48%. Investors often review this figure alongside Vistagen Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, VTGN's profit margin moved from -8634.67% to -2703.72% — a 68.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Vistagen Therapeutics's valuation or profitability profile.

Against Healthcare companies, VTGN currently prints -2703.72% for profit margin, while the sector average sits near 9.48%. That is roughly 28617.3% below the sector mean. Large gaps often invite a closer look at Vistagen Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Vistagen Therapeutics converts resources into returns. At -2703.72%, VTGN may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -8634.67% in the prior-year period — up 68.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting VTGN's profit margin (-2703.72%), review year-over-year change from -8634.67%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.